PinnedPartex.AI·Sep 12, 2025The Rise of Specialized Foundation Models in Healthcare: From Hype to RealityThe Inflection Point
Partex.AI·Oct 19Breast Cancer Awareness Week: Why New Mechanisms MatterEvery October, Breast Cancer Awareness Week reminds us how much progress has been made, and how much work remains. Breast cancer is the…
Partex.AI·Aug 29Risk- and opportunity analysis of key deals done in 1H26The first half of the year 2026 has shown many large Big Pharma deals with a general trend of growing deal sizes. While upfront-payments…
Partex.AI·Apr 14The Unified Biosystem for Drug DiscoveryIn 2026, the biggest constraint in pharmaceutical AI is no longer compute. It is not even model architecture. It is data — but not in the…
Partex.AI·Apr 72025 Oncology Licensing Deal Landscape AnalysisExecutive Summary Oncology remained the leading area of global dealmaking in 2025, supported by strong demand for differentiated therapies…
Partex.AI·Apr 3Rare Disease Therapeutics: 2025 Deal Trends and OutlookExecutive Summary The global rare-disease treatment landscape is rapidly evolving, driven by strong therapy pipelines, regulatory support…
Partex.AI·Apr 12026: From Managing Symptoms to Engineering CuresThe year 2026 is a key moment for biotechnology. In the past, many drugs worked by broadly suppressing the body or briefly blocking disease…
Partex.AI·Mar 272026 Data Watchlist: Late-Stage Clinical Trial Readouts That MatterThe year 2026 is shaping up to be a defining period for clinical drug development. Several pivotal trials are set to readout results that…
Partex.AI·Mar 24China as a Global Licensing Hub: In- and Out-Licensing Deals in the Biopharmaceutical IndustryExecutive Summary
Partex.AI·Mar 20A Deep Dive into Obesity: How 2026 Clinical Readouts Are Redefining the Weight Loss LandscapeIn 2026, the obesity market is entering a new phase. The focus is shifting from initial weight loss to long-term health management. New…